SATIOGEN PHARMACEUTICALS, INC. Patent applications |
Patent application number | Title | Published |
20130190281 | Compositions Containing Satiogens and Methods of Use - Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases. | 07-25-2013 |
20130090590 | Methods and Apparatus for Treating Obesity and Diabetes - Provided herein are methods and shunt devices for treating diabetes and obesity. Methods and shunt devices promote stimulation of secretion of intestinal L-cells and other enteroendocrine cell types. Enteroendocrine secretion is stimulated directly or indirectly by shunting bile and/or pancreatic secretion to segments of the gut more distal than would normally occur. The shunt device may be a flexible catheter that is impervious to such secretions, with a proximal end draining the pancreatic/bile duct, and a distal end residing distally within the lumen of the small or large intestine. The shunt may be inserted with minimally invasive techniques, such as by endoscopy or laparoscopy. | 04-11-2013 |
20130059807 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS - Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions. | 03-07-2013 |
20120157399 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES - Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes. | 06-21-2012 |
20110294767 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS - Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions. | 12-01-2011 |
20110152204 | Treatment of Obesity or Diabetes with Bile Acid Sequestrants - Provided herein are methods of treating obesity and diabetes with labile bile acid sequestrants. An effective amount of a labile bile acid sequestrant may be orally administered to an obese or diabetic individual. A labile bile acid sequestrant provided herein may have a low affinity in the colon or rectum of a human for at least one bile acid or bile acid mimic that stimulates L-cells. A labile bile acid sequestrant may be a non-systemic labile bile acid sequestrant. | 06-23-2011 |
20100130472 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES - Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes. | 05-27-2010 |
20100130426 | COMPOSITIONS CONTAINING SATIOGENS AND METHODS OF USE - Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases. | 05-27-2010 |